HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Megestrol Acetate

HCID 11683
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
595-33-5
Standard SMILES
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
InChIKey
RQZAXGRLVPAYTJ-GQFGMJRRSA-N
Molecular formula
C24H32O4
Average molar mass
384.5 g/mol
Monoisotopic mass
384.2300595

Overview

Megestrol Acetate can cause cancer and developmental toxicity according to state or federal government labeling requirements.

Names & identifiers

Preferred name
Megestrol Acetate
IUPAC
[(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
English name
Megestrol acetate
Molecular formula
C24H32O4
Molecular weight
384.51

Names & synonyms

MEGESTROL ACETATE595-33-5MegaceMegestryl acetateNiagestinMegeronOvabanOvaridMegace ESMegestatBDH 1298Maygace
Show more names
S4MGANia17alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dioneMEGESTROL ACETATE-D3bdh1298sc103636-MethleneProgesterone AcetateMEGESTROLACETATE,MILLEDPOWDER,USP17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
PallaceMagestinVolidanSC 10363NSC-71423MegestilMegesterol acetateSC-10363

Database identifiers

CAS
595-33-5
PubChem CID
11683
DTXSID
DTXSID9040683
ChEMBL
CHEMBL1201139
ChEBI
CHEBI:6723
UNII
TJ2M0FR8ES
EC Number
209-864-5
Nikkaji
J6.777F

Properties

Computed structural propertiesFilling in

XLogP
3.1
Topological polar surface area
60.4 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
4
Rotatable bonds
3
Heavy atoms
28
Formal charge
0
Complexity
820

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LipidsLipids -> Sterol Lipids [ST] -> Steroids [ST02] -> C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives [ST0203]
Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Animal Drugs · 2 items

Active Ingredients (Megestrol Acetate) -> FDA Greenbook

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point218.0-220.0 °C
Collision Cross Section · 2 items

198.2 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID9040683]

180.1 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
214 °C · 214°C
Boiling point
431.17 °C · 431.17°C (rough estimate)
alpha
24 · D24 +5° (chloroform)
Density
1.0474 · 1.0474 (rough estimate)
refractive index
11 ° · 11 ° (C=2, CHCl3)
storage temp.
Sealed in dry,Room Temperature
solubility
Practically insoluble in water, soluble in acetone, sparingly soluble in alcohol.
form
Solid
color
White
Merck
14 · 14,5805
BRN
1917291 · 1917291
InChIKey
RQZAXGRLVPAYTJ-GQFGMJRRSA-N
SMILES
C1(=O)C=C2[C@](C)(CC1)[C@]1([H])[C@]([H])([C@@]3([H])[C@@](CC1)(C)[C@@](OC(C)=O)(C(=O)C)CC3)C=C2C
CAS DataBase Reference
595 · 595-33-5(CAS DataBase Reference)
EWG's Food Scores
1 · 1
NCI Dictionary of Cancer Terms
megestrol acetate
FDA UNII
2 M0FR8ES · TJ2M0FR8ES
NCI Drug Dictionary
megestrol acetate
Proposition 65 List
Megestrol Acetate
NIST Chemistry Reference
Megestrol acetate(595-33-5)
EPA Substance Registry System
Megestrol acetate (595-33-5)
UNSPSC Code
12352200 · 12352200
Protein binding
Highly
Excreted unchanged in urine
56.5 · 56.5-78.4 (5-8% as metabolites)
Biological half-life
34 · 34 / -
Symbol(GHS)
8 · GHS08
Signal word
Danger
Hazard statements
360 FD · H360FD
Precautionary statements
201 · P201-P202-P280-P308+P313-P405-P501
Hazard Codes
Xn
Risk Statements
40 · 40-48
Safety Statements
22 · 22-24/25
WGK Germany
3 · 3
RTECS
4075000 · TU4075000
HS Code
29372390 · 29372390
Toxicity
50 intravenous · LD50 intravenous in mouse: 56mg/kg

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H302 (15.2%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P263, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P318, P319, P321, P330, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 125 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

Hazard Traits - Carcinogenicity; Developmental Toxicity

Megestrol acetate: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (15.2%)

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Megestrol acetate

Ambiguous-DILI-concern

1

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Safety data

wgk
3
rtecs
TU4075000
hs_code
29372390
Toxicity
LD50 intravenous in mouse: 56mg/kg
risk_code
40-48
Signal word
Danger
Symbol(GHS)
GHS08
hazard_code
Xn
safety_code
22-24/25
Hazard statements
H360FD
Precautionary statements
P201-P202-P280-P308+P313-P405-P501

Chemistry & industry

Pharmacology

Pharmacodynamics · 1 item

Megestrol is a synthetic progestin and has the same physiologic effects as natural progesterone. These effects include induction of secretory changes in the endometrium, increase in basal body temperature, pituitary inhibition, and production of withdrawal bleeding in the presence of estrogen. Mestrogel has slight glucocorticoid activity and very slight mineralocorticoid activity. This drug has no estrogenic, androgenic, or anabolic activity. The precise mechanism of megestrol’s antianorexic and anticachetic effects is unknown. Initially developed as a contraceptive, it was first evaluated in breast cancer treatment in 1967.

Mechanism of Action · 1 item

The precise mechanism by which megestrol acetate produces effects in anorexia and cachexia is unknown at the present time, but its progestin antitumour activity may involve suppression of luteinizing hormone by inhibition of pituitary function. Studies also suggest that the megestrol's weight gain effect is related to its appetite-stimulant or metabolic effects rather than its glucocorticoid-like effects or the production of edema. It has also been suggested that megestrol may alter metabolic pathyways via interferences with the production or action of mediators such as cachectin, a hormone that inhibits adipocyte lipogenic enzymes.

Biological Half-Life34 hours
Metabolism/Metabolites · 1 item

Primarily hepatic. Megestrol metabolites which were identified in urine constituted 5% to 8% of the dose administered. Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces. No active metabolites have been identified.

FDA Pharmacological Classification · 2 items

MEGESTROL ACETATE

Progestin [EPC]; Progesterone Congeners [CS]

MeSH Pharmacological Classification · 2 items

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Agents that are used to stimulate appetite. These drugs are frequently used to treat anorexia associated with cancer and AIDS.

Absorption, Distribution and Excretion · 2 items

Variable, but well absorbed orally.

The major route of drug elimination in humans is urine. Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces.

Uses & manufacturing

Use Classification · 2 items

Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Applications · 4 items

DescriptionMegestrol Acetate is the acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. It is frequently used in the treatment of patients with metastatic breast cancer. It is generally well tolerated, except that it may cause undesirable weight gain. Subsequently, it was shown that megestrol acetate produced weight gain in a variety of cachectic cancer patients. Significant reduction inserum levels of IL-1a and b,IL-2,IL-6, and TNF-o were observed in cancer patientstreated with megestrol acetate which may bear on the mechanism of improved appetite and body weight gain.It has also been postulated that the effect is, at least in part,mediated by NPY,a potent central appetite stimulant.

UsesMegestrol acetate USP (Megace) is used to treat Carcinoma of the breast or endorometrium.

UsesMegestrol acetate (Megace), a semi-synthetic progestational steroid, is the most effective known appetite stimulant at present. Previously used in patients with cancer and acquired immunodeficiency syndrome, only a few studies have considered the applicability of this drug in malnourished older persons. Megestrol acetate is useful if profound anorexia is the main manifestation of cachexia and if expected survival is weeks to months. Megace has been shown to significantly increase appetite, but not survival. In patients with a shorter predicted survival, a brief course of corticosteroids may be useful to stimulate appetite and have positive effects on nausea, pain, and asthenia.

General DescriptionMegestrol acetate, 17-hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate(Megace), is a progestin used primarily for the palliativemanagement of recurrent, inoperable, or metastatic endometrialor breast carcinoma. Megestrol acetate has also beenindicated for appetite enhancement in patients with AIDS.The biochemical basis for this use of megestrol is unclear.

Upstream & downstream products

Upstream raw materials

17α-HydroxyprogesteronePotassium borohydride16a,17a-Epoxyprogesterone1,4-BenzoquinoneAluminum tert-butoxide

Downstream products

17-Hydroxy-6-methylpregn-4-ene-3,20-dione 17-acetate
Additional notes · 1 item

DefinitionChEBI: Megestrol acetate is a steroid ester resulting from the formal condensation of the hydroxy group of megestrol with the carboxy group of acetic acid. It is an appetite stimulant used for the treatment of anorexia and cachexia. Also used for birth control and for the treatment of breast cancer. It has a role as an antineoplastic agent, an appetite enhancer, a contraceptive drug, a progestin and a synthetic oral contraceptive. It is a steroid ester, an acetate ester, a 20-oxo steroid and a 3-oxo-Delta(4) steroid. It derives from a megestrol.

Related reactions

2 records
New reaction record
HRID 325279 reaction equation
HRID 325279As product
HRID 894643 reaction equation
HRID 894643As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes